Healthcare - Biotechnology - NASDAQ - US
$ 2.62
-8.07 %
$ 148 M
Market Cap
-2.15
P/E
CASH FLOW STATEMENT
-66.7 M
OPERATING CASH FLOW
16.3 M
INVESTING CASH FLOW
71.9 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Black Diamond Therapeutics, Inc.
| Net Income | -82.4 M |
| Depreciation & Amortization | 437 K |
| Capital Expenditures | -33 K |
| Stock-Based Compensation | 9.6 M |
| Change in Working Capital | 3.69 M |
| Others | 5.09 M |
| Free Cash Flow | -66.8 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (82.4) | (91.2) | (125.6) | (67.3) | (35.3) | (8.9) | (4.6) |
| Depreciation & Amortization | 0.4 | 0.5 | 0.2 | 52 K | 47 K | 44 K | 24 K |
| Deferred Income Tax | 0 | 0 | 2.2 | 1.7 | 0 | 0 | 0.4 |
| Stock Based Compensation | 9.6 | 12.2 | 14.0 | 7.8 | 3.6 | 64 K | 5 K |
| Other Operating Activities | 2.0 | 3.3 | 2.0 | 0.5 | 6.4 | 15 K | 66 K |
| Change in Working Capital | 3.7 | (9.9) | 7.0 | 5.0 | 0.5 | 0.4 | 1.7 |
| Cash From Operations | (66.7) | (85.1) | (100.1) | (52.1) | (24.7) | (8.5) | (2.4) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 33 K | (0.2) | (2.7) | (0.1) | 21 K | 76 K | 77 K |
| Other Items | 16.4 | 53.6 | 133.3 | (281.5) | 0 | 0 | 0 |
| Cash From Investing Activities | 16.3 | 53.4 | 130.6 | (281.7) | 21 K | 76 K | 77 K |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 50 K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 82 K | 0.2 | 0.7 | 1.1 | 127.8 | 52.3 | 19.9 |
| Cash From Financing Activities | 71.9 | 0.2 | 0.7 | 214.9 | 127.8 | 52.3 | 10.0 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 21.6 | (31.5) | 31.2 | (118.9) | 103.1 | 43.8 | 7.5 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (66.8) | (85.3) | (102.9) | (52.3) | (24.7) | (8.5) | (2.4) |